Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mogrify Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, BARRON, SEAN C, who is also the busiest examiner for the portfolio with 1 pending office action. Because the entire pending workload is concentrated under 1 distinct examiner, the company's prosecution strategy is highly dependent on the specific review style of this individual.
The portfolio's active prosecution is limited to 1 distinct art unit, which corresponds to the Biotechnology & Pharmaceuticals field. This concentration in 1 distinct art unit suggests a focused technical scope for the company's current patent applications. For practitioners, this means there are no competing procedural requirements from different art units to manage at this time.
The presence of 1 pending office action across 1 distinct examiner and 1 distinct art unit indicates a very streamlined prosecution environment. BARRON, SEAN C holds the only active case, making this examiner the primary point of contact for the portfolio's current USPTO interactions. This simplicity allows for a highly targeted approach to addressing the 1 pending office action currently on record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289516 | CELL CONVERSION | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289516 | CELL CONVERSION | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289516 | CELL CONVERSION | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMogrify Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean C Barron has the most, with 1 of Mogrify Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.